MedTrace Logo

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

NCT03395899 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2024-06-18

No results posted yet for this study

Summary

International, open label, window of opportunity phase II trial that aims to evaluate the effects of immunotherapy based treatment combinations in women with untreated, histologically confirmed, operable, ER+, HER2-negative breast cancer.

Conditions

Interventions

DRUG

Atezolizumab

PD-L1 antibody

DRUG

Cobimetinib

Highly selective small-molecule inhibitor of MEK1 and MEK2

DRUG

Ipatasertib

Selective, ATP-competitive small molecule inhibitor of all three isoforms of the serine/threonine kinase Akt

DRUG

Bevacizumab

Highly specific humanized monoclonal antibody that targets VEGF

Sponsors & Collaborators

  • Kliniken Essen-Mitte

    collaborator OTHER

  • MedSIR

    collaborator OTHER

  • Asan Medical Center

    collaborator OTHER

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Peter Schmid · Queen Mary University of London

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2023-08-18
Completion
2023-08-18

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395899 on ClinicalTrials.gov